Fair Value Measurements (Tables)

9 Months Ended

Oct. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The Company’s assets and liabilities that were measured at fair value on a recurring basis were as follows:

	Fair Value Measured as of October 31, 2022
	Level 1		Level 2		Level 3		Total
	(in thousands)
Assets
Money market funds	$	92,475	$	—	$	—	$	92,475
U.S. Treasury securities	—		208,887		—		208,887
Total financial assets	$	92,475	$	208,887	$	—	$	301,362
Liabilities
Contingent earnout liability recognized upon acquisition of ViriCiti (ViriCiti Earnout)	—		—		5,337		5,337
Total financial liabilities	$	—	$	—	$	5,337	$	5,337

	Fair Value Measured as of January 31, 2022
	Level 1		Level 2		Level 3		Total
	(in thousands)
Assets
Money market funds	$	254,716	$	—	$	—	$	254,716
Total financial assets	$	254,716	$	—	$	—	$	254,716
Liabilities
Common stock warrant liabilities (Private Placement)	$	—	$	—	$	25	$	25
Contingent earnout liability recognized upon acquisition of ViriCiti (ViriCiti Earnout)	—		—		5,993		5,993
Total financial liabilities	$	—	$	—	$	6,018	$	6,018

Summary of Changes in the Fair Value of the Company's Level 3 Financial Instruments

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments:

	Private placement warrant liability		ViriCiti Earnout liability
	(in thousands)
Fair value as of January 31, 2022	$	(25)	$	(5,993)
Change in fair value included in other income (expense), net	(23)		—
Effect of foreign currency translation	—		656
Reclassification of warrants to stockholders’ equity (deficit) due to exercise	48		—
Fair value as of October 31, 2022	$	—	$	(5,337)

	Redeemable convertible preferred stock warrant liability		Private placement warrant liability		Earnout liability		ViriCiti Earnout liability
	(in thousands)
Fair value as of January 31, 2021	$	(75,843)	$	—	$	—	$	—
Private placement warrant liability acquired as part of the Merger	—		(127,888)		—		—
Contingent earnout liability recognized upon the closing of the reverse recapitalization	—		—		(828,180)		—
Change in fair value included in other income (expense), net	9,237		46,835		84,420		—
Reclassification of warrants to stockholders’ equity (deficit) due to exercise	—		51,771		—		—
Reclassification of Legacy ChargePoint preferred stock warrant liability upon the reverse capitalization	66,606		—		—		—
Issuance of earnout shares upon triggering events	—		—		501,120		—
Reclassification of remaining contingent earnout liability upon triggering event	—		—		242,640		—
Contingent Earnout liability recognized upon the acquisition of ViriCiti (ViriCiti Earnout)	—		—		—		(3,856)
Fair value as of October 31, 2021	$	—	$	(29,282)	$	—	$	(3,856)